Xu Dingqiao, Lv Yan, Wang Junsong, Yang Minghua, Kong Lingyi
Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People's Republic of China.
Center for Molecular Metabolism, School of Environmental and Biological Engineering, Nanjing University of Science and Technology, 200 Xiao Ling Wei, Nanjing, 210014, People's Republic of China.
Pharmacol Res. 2017 Jul;121:94-113. doi: 10.1016/j.phrs.2017.04.016. Epub 2017 Apr 21.
Sepsis is the major cause of morbidity and mortality in surgical patients. Huang-Lian-Jie-Du-Decoction (HLJDD), a well-known Chinese herb formula, has long been used for the treatment of sepsis. In this investigation, by leaving one herb out each time, the four component herbs of HLJDD were reformulated to four HLJDD variants Form1-4, corresponding to the removal of Phellodendri Chinensis Cortex, Scutellariae Radix, Gardeniae Fructu and Coptidis Rhizoma, respectively. Metabolomics approach combined with histological inspection, biochemical measurement and molecular biology was used to investigate the treatment effects of HLJDD and its four variants on cecal ligation and puncture (CLP) model of sepsis, which were compared to decipher the formulating principles of HLJDD. Our results showed that HLJDD exhibit the strongest therapeutic effects in the CLP models as compared with the four variants, which could be ascribed to its most significant enhancement of cholinergic anti-inflammatory pathway and inhibition of HMGB-1/TLR4/NF-κB signaling pathway. Most of all, metabolites changed specifically between groups of HLJDD and its four variants were related with the exceptional treatment effects of HLJDD.
脓毒症是外科患者发病和死亡的主要原因。黄连解毒汤(HLJDD)是一种著名的中药方剂,长期以来一直用于治疗脓毒症。在本研究中,通过每次去除一种草药,将HLJDD的四味组成草药重新配制成四种HLJDD变体Form1-4,分别对应于去除黄柏、黄芩、栀子和黄连。采用代谢组学方法结合组织学检查、生化测量和分子生物学,研究HLJDD及其四种变体对盲肠结扎穿孔(CLP)脓毒症模型的治疗效果,并进行比较以解读HLJDD的配方原则。我们的结果表明,与四种变体相比,HLJDD在CLP模型中表现出最强的治疗效果,这可能归因于其对胆碱能抗炎途径的最显著增强以及对HMGB-1/TLR4/NF-κB信号通路的抑制。最重要的是,HLJDD及其四种变体组之间特异性变化的代谢物与HLJDD的特殊治疗效果有关。